You are here

romosozumab

Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning

Xconomy

Thu, 12/12/19 - 11:02 am

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Endpoints

Fri, 06/28/19 - 10:04 am

FDA approves Evenity for osteoporosis

BioCentury

Tue, 04/9/19 - 07:03 pm

Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote

Fierce Pharma

Thu, 01/17/19 - 12:06 am

advisory panels

FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials

Endpoints

Mon, 01/14/19 - 11:37 pm

clinical trials

Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead

Endpoints

Fri, 07/13/18 - 11:57 am

An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape

Seeking Alpha

Mon, 07/24/17 - 10:44 am

FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO

Endpoints

Mon, 07/17/17 - 09:15 am

Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug

Fierce Pharma

Mon, 05/22/17 - 09:45 am

With Amgen hot on its heels, Radius races to get a jump on osteoporosis drug rivalry

Endpoints

Mon, 05/1/17 - 10:57 am

Amgen's Osteoporosis Drug Crosses a Hurdle

Investopedia

Tue, 09/27/16 - 10:14 pm

Amgen’s expectations for romosozumab take a hit as Radius lines up its rival osteoporosis drug

Endpoints

Mon, 09/19/16 - 09:53 am

Split the pot? Radius shows its osteoporosis cards in final blockbuster match with Amgen

Endpoints

Wed, 08/17/16 - 10:38 am

Amgen's bone-building osteo drug dazzles in phase 3, but could face hefty competition

BioPharma Dive

Wed, 02/24/16 - 04:48 pm

clinical trials

Amgen, UCB say osteoporosis drug meets main goal in late-stage trial

Yahoo/Reuters

Mon, 02/22/16 - 09:40 am

clinical trials

Amgen's bone drug succeeds in late-stage study

Yahoo/Reuters

Tue, 09/1/15 - 06:40 pm

Amgen Bone Drug Can Lead Market; Over 15% Upside Expected

Bidness, ETC

Wed, 08/19/15 - 09:28 am

UCB-Amgen Reveals Positive Data on Romosozumab for PMO

Yahoo/Zacks.com

Thu, 09/18/14 - 09:17 am

UCB Pharmaceuticals

low bone mineral density

Amgen Vs. Merck, Lilly In Osteoporosis Competition

Seeking Alpha

Thu, 01/9/14 - 08:33 am

UCB Pharmaceuticals

Amgen, UCB Drug Increases Bone Density in Phase 2 Trial

Drug Discovery and Development

Fri, 01/3/14 - 12:50 pm

Pages